Deep molecular response predicts survival in CML
نویسندگان
چکیده
منابع مشابه
Molecular response prediction in CML: novel ideas?
Since the introduction of tyrosine kinase inhibitor imatinib, the first targeted cancer therapy, survival of Chronic Myelogenous Leukemia (CML) patients has approached that of the normal population [1]. Treatment with TKI leads to reduction of malignant cells by several orders of magnitude, sometimes even below the level of detection of very sensitive molecular assays. Thus, in recent years ach...
متن کاملTKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
In chronic myeloid leukemia (CML) resistance against one or more BCR-ABL1 tyrosine kinase inhibitors (TKI) remains a clinical challenge. Preclinical data suggest that TKI combinations may overcome resistance. We report on a heavily pre-treated 78 year-old female patient with CML who developed multi-resistant blast crisis with bone marrow fibrosis and a Ph- clone. Treatment with ponatinib result...
متن کاملPredicting response in CML.
study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. Leen AM, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Predicting response in chronic myeloid leukemia (CML) patients who are offered tyrosine kinase inhibitor (TKI) second-line therapy is vital...
متن کاملHematological and molecular response evaluation of CML patients on imatinib.
BACKGROUND The BCR-ABL tyrosine kinase is a well-validated therapeutic target in Chronic Myeloid Leukemia (CML). Imatinib mesylate (formerly STI-571), a tyrosine kinase inhibitor is highly effective at the hematological, cytogenetic and molecular level in CML. AIMS To evaluate hematological and molecular response in CML patients on Imatinib and also the side effects of the therapy if any. M...
متن کاملRMP predicts survival and adjuvant TACE response in hepatocellular carcinoma
Adjuvant transcatheter arterial chemoembolization (TACE) protects against hepatocellular carcinoma (HCC) and is associated with reduced disease recurrence and improved outcome after surgery. However, deterioration of liver function after TACE negatively impacts the patient prognosis and limits it use as an option to prolong survival. We analyzed two independent cohorts that included a total of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Clinical Oncology
سال: 2013
ISSN: 1759-4774,1759-4782
DOI: 10.1038/nrclinonc.2013.235